Oragenics Inc. (OGEN)
| Market Cap | 86.01M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.62M |
| Shares Out | 59.67M |
| EPS (ttm) | -0.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $0.929 |
| Previous Close | $0.950 |
| Change ($) | -0.021 |
| Change (%) | -2.24% |
| Day's Open | 0.955 |
| Day's Range | 0.902 - 1.030 |
| Day's Volume | 30,380,465 |
| 52-Week Range | 0.386 - 1.490 |
Oragenics (OGEN) stock is soaring higher on Thursday from new coronavirus vaccine news after just receiving a boost last week. The post OGEN Stock Alert: Why Oragenics Shares Are Flying Again ...
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Issues Letter to Stockholders
Oragenics (OGEN) is seeing shares of OGEN stock take off on Thursday on a news update for its vaccine to treat the novel coronavirus. The post OGEN Stock Alert: 14 Things to Know About Orageni...
TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS ENTERS INTO MATERIAL TRANSFER AGREEMENT WITH ADJUVANCE TECHNOLOGIES FOR COVID-19 VACCINE ADJUVANT
TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS ANNOUNCES CLOSING OF $6.5 MILLION REGISTERED DIRECT OFFERING
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. Announces $6.5 Million Registered Direct Offering
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Closing of $6.0 Million Underwritten Public Offering
TAMPA, Fla.--(BUSINESS WIRE)--ORAGENICS PRICES $5.25 MILLION COMMON STOCK OFFERING
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Announces Proposed Underwritten Public Offering
Oragenics is planning to launch clinical trials of its coronavirus vaccine in early 2021. OGEN stock is soaring on the news.
TAMPA, Fla.--(BUSINESS WIRE)--FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine
TAMPA, Fla. & TUSTIN, Calif.
TAMPA, Fla.--(BUSINESS WIRE)--Preclinical Study Shows SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Produces Neutralizing Antibodies
About OGEN
Oragenics develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring compound for use in weight loss; and SMaRT Replacement Therapy, a top... [Read more...]
| Industry Biotechnology | Founded 1996 |
| CEO Dr. Alan F. Joslyn | Employees 7 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol OGEN |